-
Sulforaphane Suppresses NLRP3 in Ulcerative Colitis
2026-09-02
The reference study integrates a dextran sodium sulfate mouse model with RAW264.7 cell experiments to show that Sulforaphane reduces oxidative stress and suppresses NLRP3 inflammasome activation during colitis. Its main practical contribution is a mechanistic link between reactive oxygen species and inflammatory signaling, while its findings remain preclinical and model-dependent.
-
Cell Counting Kit-8 Plus for Ferroptosis Studies
2026-09-02
Cell Counting Kit-8 Plus provides a fast, water-soluble WST-8 readout for connecting colorectal cancer cell survival with SLC11A1-associated ferroptosis resistance. This workflow emphasizes assay design, metabolic confounder controls, and orthogonal validation rather than treating absorbance as a direct cell count.
-
Deracoxib and Piroxicam in Canine Osteosarcoma
2026-09-01
This 2005 study compared deracoxib and piroxicam across canine osteosarcoma cell lines and found that deracoxib produced more consistent, concentration-dependent loss of viability. Its selective effect relative to fibroblasts supports further investigation, while the absence of DNA fragmentation cautions against assuming that apoptosis explains the observed cytotoxicity.
-
Topotecan HCl Workflows for DNA Damage Studies
2026-09-01
Topotecan HCl provides a controllable topoisomerase 1 inhibitor workflow for linking replication-associated DNA damage with cell death, while supporting lung, prostate, breast, and exploratory neuroinflammation assays. This guide combines product-backed exposure ranges with practical controls, endpoint selection, and safeguards against confusing general toxicity with pathway-specific effects.
-
11β-HSD1 Inhibition in Liver Fibrosis
2026-08-31
A 2025 mouse study shows that a novel 11β-HSD1 inhibitor reduces thioacetamide-associated liver fibrosis through coordinated suppression of Notch signaling and enhancement of natural killer cell responses. The work links local cortisol regulation with hepatic stellate-cell activation and immune-mediated clearance, providing a mechanistic framework for evaluating new antifibrotic strategies while underscoring the limits of translation from a toxin-induced model.
-
Risedronate Sodium: Workflows for Bone Research
2026-08-31
Risedronate Sodium gives researchers a practical route to study FPPS-dependent osteoclast biology, bone resorption, and formulation-enhanced delivery. This guide translates published nanotransfersome–microneedle data into bench workflows, assay choices, and troubleshooting strategies for skeletal and exploratory pulmonary research.
-
Adefovir (GS-0393) Research Workflows
2026-08-30
Adefovir (GS-0393) supports two complementary research applications: mechanistic HBV polymerase studies and quantitative OAT1 transport profiling. This guide converts those properties into practical assay workflows, exposure-aware comparisons, and troubleshooting strategies for reproducible hepatitis B virus research.
-
FBXO22 Recruitment Ligands Expand Protein Degradation
2026-08-29
This 2025 bioRxiv preprint introduces chemical probes that define two complementary ways to engage the cancer-associated E3 ligase FBXO22: selective self-degradation and recruitment of the ligase to new protein targets. The identification of 2-pyridinecarboxaldehyde as a reversible cysteine-reactive degron expands the ligand space available for targeted protein degradation while providing practical probes for studying FBXO22 biology.
-
Heparin Sodium at the Nanovesicle–Coagulation Interface
2026-08-28
Heparin sodium is more than a standard anticoagulant: it can anchor reproducible coagulation assays while providing a carefully bounded probe of heparan sulfate proteoglycan-dependent nanovesicle uptake. This article connects the reference study on Cistanche deserticola nanovesicles and Sertoli-cell recovery with practical translational workflows, emphasizing assay controls, mechanistic limits, and research-only interpretation.
-
GM 6001 (Galardin): Assay Reliability Guide
2026-08-28
A practical, scenario-based guide to using GM 6001 (Galardin), SKU A4050, when MMP activity complicates viability, proliferation, migration, or extracellular matrix assays. It covers mechanism, DMSO stock preparation, controls, interpretation, and vendor-selection criteria supported by product data and cited research.
-
Intestinal TM6SF2 Protects Against MASH
2026-08-27
A 2025 Nature Metabolism study shows that intestinal epithelial TM6SF2 protects against MASH by maintaining barrier integrity and limiting lipid-driven microbiota and lysophosphatidic acid signaling. Conditional knockout, fecal-transfer, co-housing, and pharmacological experiments establish a causal gut–liver pathway and identify LPA receptor blockade as a testable intervention.
-
Polybrene for Mechanism-First Cell Engineering
2026-08-27
Polybrene (Hexadimethrine Bromide) can improve viral gene delivery while protecting the interpretability of mitochondrial metabolism experiments. This guide connects transduction design with the TCAIM–OGDH findings and emphasizes controls that separate delivery effects from biological mechanisms.
-
PP 1: Src Family Tyrosine Kinase Inhibitor
2026-08-26
PP 1 enables controlled dissection of Lck, Fyn, Lyn, and related signaling in cancer and immune-cell models. This workflow connects kinase perturbation with interpretable radiopathomics, offering a practical route from phosphotyrosine biology to response-stratification hypotheses without overstating clinical relevance.
-
Fosinopril Sodium: Translational ACE Inhibition
2026-08-26
A strategic guide to using Fosinopril sodium as a mechanistically defined ACE inhibitor in hypertension research, cardiovascular disease models, and cardio-renal translation, with practical guidance on prodrug biology, assay design, formulation, and translational endpoints.
-
VERTIS CV: Ertugliflozin and Cardiovascular Outcomes
2026-08-25
The VERTIS CV trial established that ertugliflozin was noninferior to placebo for major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Its randomized, double-blind, event-driven design provides a rigorous framework for interpreting cardiovascular safety, while the neutral primary result places limits on claims of cardiovascular superiority.